Results 131 to 140 of about 1,148,410 (327)
A relação entre patentes farmacêuticas e programas públicos de saúde
Cadernos de Campo, 2012 This paper discusses how the patent was set up mainly relating to the pharmaceutical sector since 1995 with the implementation of the TRIPS agreement.
José Flávio de Castro
doaj
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones +3 more
wiley +1 more source
FermentationIt is widely known that mushrooms present several properties with applications in the medicinal and pharmaceutical sectors, including antimicrobial, immunomodulatory, antioxidant, hypotensive, neuroprotective, and anti-inflammatory activities.
Walter José Martinez-Burgos +10 more
doaj +1 more source
Pharmaceutical patents: reconciling the human right to health with the incentive to invent. [PDF]
Drug Discov Today, 2020 Khachigian LM.
europepmc +1 more source
Health Biotechnology Innovation for Social Sustainability -A Perspective from China [PDF]
, 2011 China is not only becoming a significant player in the production of high-tech products, but also an increasingly important contributor of ideas and influence in the global knowledge economy.
Chen, Yantai, Ely, Adrian
core +1 more source
Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley +1 more source
Pharmaceutical; trademark; patents; news [PDF]
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 2019 Richard Milchior, Séverine Charbonnel
+4 more sources
The Influence of the Andean Intellectual Property Regime on Access to Medicines in Latin America [PDF]
, 2014 This chapter is a contribution to Balancing Wealth and Health: Global Administrative Law and the Battle over Intellectual Property and Access to Medicines in Latin America, Rochelle Dreyfuss & César Rodríguez-Garavito, eds.
Alter, Karen J., Helfer, Laurence R.
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman +9 more
wiley +1 more source
07-05 “The Politics of Patents and Drugs in Brazil and Mexico: The Industrial Bases of Health Activism” [PDF]
This paper analyzes the politics of intellectual property (IP) and public health in Brazil and Mexico. Both countries introduced pharmaceutical patents in the 1990s, to comply with their international obligations.
Ken Shadlen
core